A phase I study of IRISOX (irinotecan/S-1/oxaliplatin) in the second-line treatment for gemcitabine-refractory pancreatic cancer

被引：0
|
作者：
Miyata, E. [1 ]
Okuwaki, K. [1 ]
Imaizumi, H. [2 ]
Kida, M. [1 ]
Iwai, T. [1 ]
Yamauchi, H. [1 ]
Kaneko, T. [1 ]
Hasegawa, R. [1 ]
Adachi, K. [1 ]
Tadehara, M. [1 ]
Koizumi, W. [1 ]
机构：
[1] Kitasato Univ, Sch Med, Gastroenterol, Sagamihara, Kanagawa, Japan
[2] Sagamino Hosp, Japan Community Hlth Care Org, Gastroenterol, Sagamihara, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
721P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer
    Mizuno, Nobumasa
    Yamao, Kenji
    Komatsu, Yoshito
    Munakata, Masaki
    Ishiguro, Atsushi
    Yamaguchi, Taketo
    Ohkawa, Shinichi
    Kida, Mitsuhiro
    Ioka, Tatsuya
    Takeda, Koji
    Kudo, Toshihiro
    Kitano, Masayuki
    Iguchi, Haruo
    Tsuji, Akihito
    Ito, Tetsuhide
    Tanaka, Masao
    Furuse, Junji
    Hamada, Chikuma
    Sakata, Yuh
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [22] Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
    Tschoep-Lechner, Katharina Elisabeth
    Milani, Valeria
    Berger, Frank
    Dieterle, Nelli
    Abdel-Rahman, Sultan
    Salat, Christoph
    Issels, Rolf-Dieter
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2013, 29 (01) : 8 - 16
  • [23] GEMCITABINE AND CISPLATIN COMBINED WITH REGIONAL HYPERTHERMIA AS SECOND-LINE TREATMENT IN PATIENTS WITH GEMCITABINE-REFRACTORY ADVANCED PANCREATIC CANCER
    Lechner, Katharina
    Berger, Frank
    Dieterle, Nelli
    Abdel-Rahman, Sultan
    Salat, Christoph
    Issels, Rolf
    ANNALS OF ONCOLOGY, 2012, 23 : 62 - 62
  • [24] Impact of S-1 in Patients with Gemcitabine-refractory Pancreatic Cancer in Japan
    Nakai, Yousuke
    Isayama, Hiroyuki
    Sasaki, Takashi
    Sasahira, Naoki
    Kogure, Hirofumi
    Hirano, Kenji
    Tsujino, Takeshi
    Ijichi, Hideaki
    Tateishi, Keisuke
    Tada, Minoru
    Omata, Masao
    Koike, Kazuhiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (08) : 774 - 780
  • [25] Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer.
    Ueno, Makoto
    Ohkawa, Shinichi
    Kobayashi, Noritoshi
    Sugimori, Kazuya
    Kawaguchi, Yoshiaki
    Kobayashi, Satoshi
    Taguri, Masataka
    Yamanaka, Takeharu
    Mine, Tetsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [26] S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure
    Todaka, Akiko
    Fukutomi, Akira
    Boku, Narikazu
    Onozawa, Yusuke
    Hironaka, Shuichi
    Yasui, Hirofumi
    Yamazaki, Kentaro
    Taku, Keisei
    Machida, Nozomu
    Sakamoto, Takeshi
    Tomita, Hideharu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (06) : 567 - 572
  • [27] Phase I study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy in gemcitabine-refractory pancreatic cancer patients.
    Morizane, C.
    Okusaka, T.
    Furuse, J.
    Ishii, H.
    Ueno, H.
    Ikeda, M.
    Ogura, T.
    Nakachi, K.
    Suzuki, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 272 - 273
  • [28] Second-Line Therapy for Gemcitabine-Refractory Pancreatic Cancer: Is There a Standard? The Almhanna/Kim Article Reviewed
    Ko, Andrew H.
    ONCOLOGY-NEW YORK, 2008, 22 (10): : 1190 - +
  • [29] A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
    Suzuki, Eiichiro
    Ikeda, Masafumi
    Okusaka, Takuji
    Nakamori, Shoji
    Ohkawa, Shinichi
    Nagakawa, Tatsuya
    Boku, Narikazu
    Yanagimoto, Hiroaki
    Sato, Tosiya
    Furuse, Junji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1141 - 1146
  • [30] The role of S-1 in gemcitabine-refractory pancreatic cancer: A retrospective single-institution study
    Nakai, Y.
    Isayama, H.
    Sasaki, T.
    Sasahira, N.
    Hirano, K.
    Tsujino, T.
    Tada, M.
    Kawabe, T.
    Omata, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345